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Summary
BACKGROUND: SARS-CoV-2/COVID-19, which
emerged in China in late 2019, rapidly spread across the
world with several million victims in 213 countries. Switzer-
land was severely hit by the virus, with 43,000 confirmed
cases as of 1 September 2020.
AIM: In cooperation with the Federal Office of Public
Health, we set up a surveillance database in February
2020 to monitor hospitalised patients with COVID-19, in
addition to their mandatory reporting system.
METHODS: Patients hospitalised for more than 24 hours
with a positive polymerase chain-reaction test, from 20
Swiss hospitals, are included. Data were collected in a
customised case report form based on World Health Or-
ganisation recommendations and adapted to local needs.
Nosocomial infections were defined as infections for which
the onset of symptoms was more than 5 days after the pa-
tient’s admission date.
RESULTS: As of 1 September 2020, 3645 patients were
included. Most patients were male (2168, 59.5%), and
aged between 50 and 89 years (2778, 76.2%), with a me-
dian age of 68 (interquartile range 54–79). Community
infections dominated with 3249 (89.0%) reports. Comor-
bidities were frequently reported, with hypertension (1481,
61.7%), cardiovascular diseases (948, 39.5%) and dia-
betes (660, 27.5%) being the most frequent in adults; res-
piratory diseases and asthma (4, 21.1%), haematological
and oncological diseases (3, 15.8%) were the most fre-
quent in children. Complications occurred in 2679 (73.4%)
episodes, mostly respiratory diseases (2470, 93.2% in
adults; 16, 55.2% in children), and renal (681, 25.7%) and
cardiac (631, 23.8%) complications for adults. The second
and third most frequent complications in children affect-
ed the digestive system and the liver (7, 24.1%). A target-
ed treatment was given in 1299 (35.6%) episodes, most-
ly with hydroxychloroquine (989, 76.1%). Intensive care
units stays were reported in 578 (15.8%) episodes. A total
of 527 (14.5%) deaths were registered, all among adults.
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CONCLUSION: The surveillance system has been suc-
cessfully initiated and provides a robust set of data for
Switzerland by including about 80% (compared with offi-
cial statistics) of SARS-CoV-2/COVID-19 hospitalised pa-
tients, with similar age and comorbidity distributions. It
adds detailed information on the epidemiology, risk factors
and clinical course of these cases and, therefore, is a valu-
able addition to the existing mandatory reporting.
Keywords: SARS-CoV-2, COVID-19, surveillance,
Switzerland, hospitalisations
Introduction
With almost 27 million confirmed cases, of which 70.5%
recovered, and more than 850,000 deaths [1], the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) /
coronavirus disease 2019 (COVID-19) pandemic has had
a massive impact on all aspects of everyday life, including
politics, travel and economics. The virus was initially iden-
tified in a cluster of Chinese adult patients with pneumonia
of unknown cause [2], incriminating a large seafood and
animal market in Wuhan City as the source of the outbreak;
but rapidly spread via person-to-person transmission.
Since then, 213 countries and territories have been affected
[3].
On 30 January 2020, the World Health Organization
(WHO) declared the outbreak a Public Health Emergency
of International Concern (PHEIC). The WHO emphasised
the urgent need to coordinate international efforts to in-
vestigate and better understand this novel coronavirus, to
minimise the threat in affected countries and to reduce the
risk of further international spread [4]. The WHO designed
various study protocols for early investigation of the out-
break, including a global anonymised clinical data plat-
form (the “nCoV Data Platform”) to enable state parties of
the International Health Regulations (IHR) (2005) to share
with the WHO anonymised clinical data and information
related to patients with suspected or confirmed infections
with SARS-CoV-2 (collectively “Anonymized nCoV Da-
ta”) [5].
The first patient with COVID-19 in Switzerland was re-
ported on 25 February 2020 in the canton of Ticino, earlier
than in most European countries due to its proximity to
Italy and cross-border commuting. In order to prevent and
monitor the spread of the disease in Switzerland, suspicion
of COVID-19 cases by clinicians were reported to the Fed-
eral Office of Public Health (hereafter FOPH) through an
obligatory declaration form [6]. The number of confirmed
cases rose rapidly to more than 8000 positive cases and
66 deaths within only a month after the start of the epi-
demic in Switzerland. Compared with its neighbour coun-
tries, Switzerland has similarly suffered from the pandemic
with a cumulative incidence of 496.5 confirmed cases per
100,000 habitants (Germany 264.7, France 449.9, Italy
448.4), but with an overall lower cumulative incidence of
death at 200.9 deaths per 1,000,000 inhabitants (Germany
111.6, France 471.2, Italy 586.2) as of 4 September 2020
[7].
Early analysis and preparations by officials for the advent
of the COVID-19 pandemic in Switzerland, including
identification of risk groups and forecasting, were based
on Chinese data. However, the Chinese population differs
from the Swiss population, and such models were therefore
misleading and inaccurate. Based on our experience with
the hospital-based surveillance of influenza cases in
Switzerland [8] and in collaboration with the FOPH, we
developed a surveillance system of hospitalised
COVID-19 cases in early February. We aimed to:
1. Test the adaptability of the influenza system to other
infectious diseases and quantify the workload to be
able to react faster to future epidemics.
2. Monitor the evolution of hospitalised COVID-19 cases
in Switzerland, alongside the mandatory reporting sys-
tem.
3. Provide a reliable, harmonised, in-depth dataset for
hospitalised COVID-19 cases in Switzerland that can
be used for decision-making and public health purpos-
es.
The aim of the current manuscript is to present a profile of
patients hospitalised with COVID-19 during the first epi-
demic wave in Switzerland.
Study design and procedures
This study was submitted to and approved by the Geneva
Ethics Committee (CCER) and by all hospitals’ local
Ethics Committee through the Swissethics BASEC sub-
mission system, under reference 2020-00827.
Inclusion
The study was designed to capture most of the severe
COVID-19 cases in Switzerland by including hospitalised
patients from 20 large cantonal and university hospitals. To
ease the process and to minimise the time taken to devel-
op the system, we first contacted the participating hospi-
tals of the influenza pilot surveillance system [8]; seven
of which agreed to participate (Hôpitaux Universitaires de
Genève, Kantonsspital St Gallen, Ospedaliero Cantonale
Ticino, Hôpital du Valais, Centre Hospitalier Universitaire
du Canton de Vaud, Universitätsspital Zürich, Univer-
sitäts-Kinderspital Zürich). Since patients were more likely
to be sent to large hospitals with more capacity and better
means to treat a novel disease, the system also captured
patients from other large university and cantonal hospitals
that agreed to participate: Universitätsspital Basel, Insel-
spital Bern, Kantonsspital Graubünden, Luzerner Kanton-
sspital (including Kinderspital Luzern), Spitäler
Schaffhausen Kantonsspital, Thurgau Hospital Group, and
smaller cantonal hospitals (Hôpital de Fribourg, Kanton-
sspital Aarau, Kantonsspital Winterthur, Kantonsspital
Nidwalden, and Klinik Hirslanden Zürich). Three of the
smaller hospitals (Fribourg, Aarau and Winterthur) con-
tributed only paediatric cases. We also included three pae-
diatric hospitals, separate from their adult counterparts:
Universität Kinderspital Basel, Ostschweizer Kinderspital,
and Kinderspital Zürich. The Kantonsspital St. Gallen also
included cases from all public hospitals of the canton: they
were included by the identical infection control team.
Patients, regardless of age or gender, with a polymerase
chain-reaction (PCR) confirmed COVID-19 diagnosis and
who were hospitalised for more than 24 hours were in-
cluded in the database. The data were collected by infec-
tion control specialists or other physicians, dedicated study
nurses or medical students of the participating centres un-
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der the supervision of physicians and stored anonymous-
ly in a secure REDCap database [9] located in the Clini-
cal Research Centre of the University Hospitals of Geneva.
Data entry started on 1 March 2020 and is still ongoing.
Data were also collected retrospectively.
Questionnaire
Data are collected on the case report form (CRF) devel-
oped for the influenza surveillance pilot [8], with relevant
COVID-19 additions. This CRF is split in two parts: a
compulsory part contains inclusion criteria, demographics,
case declaration (classification, date of detection and date
of symptoms, laboratory sample information), admission
details (hospitalisation ward, origin of patient, severity at
admission), and follow-up forms. The optional part de-
scribes the patient’s stay in more detail with descriptions of
complications, intensive/intermediate care stays, treatment
and risk factors in a clinical complementary information
form. The CRF is presented in appendix 1.
Since the system was put in place when movement and
contact tracing became difficult, we selected only part of
the recommended WHO COVID-19 CRF [10] and of the
FOPH obligatory declaration form [6]. We removed any
information about travel to foreign countries or ethnicity.
However, we kept employment in healthcare facilities as
an important risk factor. The follow-up and daily forms
of the WHO CRF were deemed too time consuming to
complete by participating hospitals, and were therefore
discarded in favour of the influenza CRF structure. Re-
porting of complications and underlying medical condi-
tions were also similar to the influenza CRF with small
additions of conditions shown to be of importance either
as risk factors (e.g., hypertension, angiotensin converting-
enzyme inhibitor treatment, obesity), or as consequences
of the SARS-CoV-2 infection (acute respiratory distress
syndrome (ARDS), thrombosis/embolism). To assess the
severity of the disease at admission, we also added the
CURB-65 score [11] for adults (CURB-65 = confusion,
blood urea >42,8 mg/dl, respiratory rate> 30/min, blood
pressure <90/60 mm Hg, age >65), and a similar severity
score for children based on the expertise of the partici-
pating paediatric infectious disease specialists. Finally, we
classified cases as community-acquired or nosocomial, by
defining nosocomial cases to be those for which the onset
of symptoms was more than 5 days after the patient’s ad-
mission date. This time limit was to account for the incu-
bation time for the virus and is in line with the national rec-
ommendations of Swissnoso [12].
As a surveillance tool and because of the rapid growth of
the epidemic, basic epidemiological information had to be
reported within 48 hours, comprising at minimum the in-
clusion criteria, demographics and case declaration forms
in order to report the new cases and their location with
little delay. Additional information on the hospitalisation
itself (admission, follow-up and clinical information) were
recorded as soon as possible, depending on the severity of
the epidemic and local issues.
The database records entries as COVID-19 episodes rather
than per patient, with the possibility to link two episodes.
A new episode was defined as readmission into hospital
more than 30 days after the previous discharge. If a transfer
between hospitals occurred, a new record was created in
the destination hospital. The database and CRF implemen-
tation were tested by the participating sites at the time of
deployment and tweaked on the basis of their feedback.
Small additional changes were made as the database was
already in production when new information about the dis-
ease became available (e.g., thrombosis/embolism).
Data analysis
The data presented in this manuscript were extracted early
on 1 September 2020, to ensure all patients up to and in-
cluding 31 August 2020 were presented.
The data were processed through a set of Python (version
3.8.4) scripts, which assessed their quality and removed
115 ineligible records. Patient level data (year of birth and
gender) were taken as is and age was derived by using the
date of inclusion in the system. Episode data were aggre-
gated by summing the hospitalisations under a same record
ID for questions “Yes/No/Unknown”, “Unknown” answers
being treated as missing values, “Yes” as 1 and “No” as 0.
The outcome of the episode was taken in the last recorded
hospitalisation for that episode.
Finally, the week used in the figures of this manuscript is
the week of interest for the system, defined as:
1. The week of the sample collection date (equivalent to
the diagnosis) for nosocomial cases or the week of ad-
mission into the hospital for other cases.
2. The week of the sample collection date, if the case is
not nosocomial but the hospital entry date is missing.
3. The week of the inclusion date in the database, if the
case is nosocomial but the sample collection date is
missing, or if both the sample collection and hospital
entry dates were missing.
Characteristics of patients
Demographics
As of 31 August 2020, 3650 episodes in 3645 patients have
been recorded in the database, with 66 patients hospitalised
more than once for the same episode. Figure 1 shows the
age and gender distribution of patients in the database and
table 1 shows their baseline characteristics. Overall, 2168
(59.5%) patients were male and 1477 (40.5%) female, and
the median age was 68 years (interquartile range [IQR]
54–79). Most were aged between 50 and 89 years (2778,
76.2%), followed by the age groups 40 to 49 years (299,
8.2%), 90 to 99 years (215, 5.9%) and 30 to 39 years (185,
5.1%). Among children, patients between 13 and 19 years
and patients between a month and less than a year were
predominant, with 24 (0.7%; 35.3% of all children) and 23
(0.6%; 33.8% of all children) patients, respectively.
The majority of episodes were community acquired (3249,
89.0%), and 349 (9.6%) were nosocomial or of unknown
source (52, 1.4%). Nosocomial cases were found less often
in children (4.4% of all episodes in children versus 9.7%
of all episodes in adults). Figure 2 shows the evolution
of the number of episodes throughout the epidemic. The
first episodes were recorded in week 2020-09, followed
by a rapid rise to about 900 episodes in week 2020-13
before decreasing and stagnating from week 2020-20 on-
wards with few episodes declared. A small increase in
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week 2020-25 was observed. At the time of writing, the
number of new cases had stabilised to around 30 per week.
Potential risk factors for COVID-19
The risk factors recorded, categorised into comorbidities
(typically, chronic diseases), pregnancy status for women
Figure 1: Population breakdown of the 3645 patients hospitalised with COVID 19 between 1 March and 31 August 2020, by age and gender.
Figure 2: Distribution of SARS-CoV-2/COVID-19 episodes registered in the database by origin of infection.
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Gender Male 2168 59.5
Female 1477 40.5
















and history of smoking are split by age group for adults and
children in tables 2 and 3, respectively. The Charlson Co-
morbidity Index [13] was used to calculate an overall risk
score, of which the median value was 3.0 (IQR 1–6) for
both the overall population and adult patients. This score
had a median value of 0.5 (IQR 0–1.75) among children.
In adults, comorbidities were recorded for 2401 (67.0%)
episodes, with 1884 having more than one comorbidity.
Among those, hypertension was the most frequent comor-
bidity, with 1481 (61.7%) occurrences, followed by chron-
ic cardiovascular diseases (948, 39.5%) and diabetes (660,
27.5%). Chronic respiratory diseases were reported in 515
(21.4%) episodes, renal disease in 500 (20.8%) and neuro-
logical impairment in 386 (16.1%). Oncological patholo-
gies (315, 13.1%), asthma (204, 8.5%), dementia (198,
8.2%), liver diseases (144, 6.0%) and immunosuppression
(128, 5.3%) were registered less often, and other comor-
bidities were observed only sporadically (<5%). Informa-
tion about comorbidities was missing for 574 (16.0%)
episodes among adults.
In children, comorbidities were recorded for 19 (27.9%)
episodes, with 9 having more than one comorbidity. Res-
piratory diseases and asthma were the most frequent co-
morbidities, occuring in 4 (21.1%) episodes each, followed
by haematological and oncological pathologies (3, 15.8%),
renal and liver diseases alongside neurological impairment
and immunosuppression (2, 10.5%). Finally, diabetes, hy-
pertension and cardiovascular diseases each occured in
one (5.3%) episode. Information about comorbidities was
missing for 7 (10.3%) episodes in children.
Complications
Tables 2 and 3 also show lists of complications encoun-
tered in COVID-19 episodes in adults and children, respec-
tively. Out of the 3650 episodes, at least one complica-
tion due to the COVID-19 infection was reported in 2679
(73.4%), 2650 being in adults and 29 in children. Multi-
ple complications occurred in 1961 adult episodes and 14
child episodes. Overall, 565 episodes with complications
involved a stay on the intensive care unit (ICU), 560 of
which were in adults.
Table 2: Characteristics of SARS-CoV-2/COVID-19 episodes, out-
comes and related consequences (complications) encountered in reg-









Smoked in the last 10 years Unknown 1537 42.9
No 1808 50.5
Yes 237 6.6
Pregnancy (females aged be-




Had at least one comorbidity Unknown 574 16
Yes 2401 67
No 607 16.9
– Respiratory diseases Unknown 3 0.1
No 1883 78.4
Yes 515 21.4
– Asthma Unknown 4 0.2
No 2193 91.3
Yes 204 8.5
– Diabetes Unknown 1 0
No 1740 72.5
Yes 660 27.5
– Hypertension Unknown 3 0.1
No 917 38.2
Yes 1481 61.7
– Cardiovascular diseases Unknown 4 0.2
No 1449 60.3
Yes 948 39.5
– Renal diseases Unknown 4 0.2
No 1897 79
Yes 500 20.8
– Liver diseases Unknown 3 0.1
No 2254 93.9
Yes 144 6
– Neurological impairment Unknown 8 0.3
No 2007 83.6
Yes 386 16.1





– Oncological diseases Unknown 7 0.3
No 2079 86.6
Yes 315 13.1





– Dementia Unknown 12 0.5
No 2191 91.3
Yes 198 8.2
– Transplantation of solid organs Unknown 4 0.2
No 2374 98.9
Yes 23 1
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– Tuberculosis Unknown 16 0.7
No 2363 98.4
Yes 22 0.9
– Other diseases Unknown 3 0.1
No 968 40.3
Yes 1430 59.6
Had at least one complication Unknown 587 16.4
No 345 9.6
Yes 2650 74










– Respiratory complications Unknown 6 0.2
No 174 6.6
Yes 2470 93.2
– Acute respiratory distress syn-















– Cardiovascular complications Unknown 32 1.2
No 1987 75
Yes 631 23.8
– Digestive complications Unknown 41 1.5
No 2111 79.7
Yes 498 18.8
– Liver complications Unknown 28 1.1
No 2112 79.7
Yes 510 19.2
– Renal complications Unknown 28 1.1
No 1941 73.2
Yes 681 25.7





– Osteo-articular complications Unknown 34 1.3
No 2489 93.9
Yes 127 4.8
– Thrombosis/embolism Unknown 34 1.3
No 2406 90.8
Yes 210 7.9
– Other bacterial infection Unknown 38 1.4
No 2283 86.2
Yes 329 12.4
– Other non-bacterial infection Unknown 33 1.2
No 2485 93.8
Yes 132 5
– Other complications Unknown 19 0.7
No 1475 55.7
Yes 1156 43.6











– Hydroxychloroquine No 310 23.9
Yes 985 76.1
– Interferon No 1293 99.8
Yes 2 0.2
– Lopinavir/ritonavir No 620 47.9
Yes 675 52.1
– Remdesivir No 1150 88.8
Yes 145 11.2
– Tenofovir No 1294 99.9
Yes 1 0.1
– Ribavirin No 1295 100
Yes 0 0
– Other treatment No 1126 86.9
Yes 169 13.1







HIV = human immunodeficiency virus; ICU = intensive care unit
In adults, respiratory complications were dominant, with
2470 (93.2%) occurrences. Pneumonia was found in 2162
episodes (87.5% of respiratory complications), of which
2096 (96.9%) were found to be caused solely by
COVID-19. Acute respiratory distress syndrome (ARDS)
was reported in 557 (22.5%) cases of respiratory complica-
tions. Renal complications were observed in 681 (25.7%)
adult episodes, followed by cardiac (631, 23.8%), liver
(510, 19.2%), digestive (498, 18.8%) and neurological
(436, 16.5%) complications, and bacterial infections other
than pneumonia (329, 12.4%). Other complications were
present in less than 10% of the episodes and included
thrombosis and embolisms (210, 7.9%), ear/nose/throat
complications (ENT; 193, 7.3%; among which 8 [4.1%]
were acute otitis media), non-bacterial infections (132,
5.0%) and osteo-articular complications (127, 4.8%).
In children, respiratory complications were also predomi-
nant with 16 (55.2%) occurrences. Pneumonia (11, 68.8%)
was directly caused by COVID-19 in 10 (90.9%) cases of
pneumonia. These comprised ARDS in 4 (25.0%) episodes
in children. In contrast to adults, digestive and liver com-
plications were the second most frequent complications,
were reported in 7 (24.1%) children’s episodes with com-
plications, followed by cardiac (6, 20.7%), ENT (5, 17.2%;
of which one was a case of acute otitis media) and neuro-
logical (4, 13.8%) complications. Finally, renal complica-
tions and thrombosis/embolism were each reported in three
episodes (10.3% of episodes with complications), and non-
bacterial infections in 2 (6.9%). Other bacterial infections
as well as osteo-articular complications were not reported
in children.
Other types of complications were registered in 1170
episodes (43.6% of episodes with complications). Ageusia,
anaemia and deconditioning syndromes were most often
reported. Anosmia was reported in 4 (0.2%) COVID-19
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Table 3: Characteristics of SARS-CoV-2/COVID-19 episodes, out-
comes and related consequences (complications) encountered in reg-










Smoked in the last 10 years Unknown 44 64.7
No 22 32.4
Yes 2 2.9
Pregnancy (female aged between




Had at least one comorbidity Unknown 7 10.3
Yes 19 27.9
No 42 61.8
– Respiratory diseases No 15 78.9
Yes 4 21.1
– Asthma No 15 78.9
Yes 4 21.1
– Diabetes No 18 94.7
Yes 1 5.3
– Hypertension No 18 94.7
Yes 1 5.3
– Cardiovascular diseases No 18 94.7
Yes 1 5.3
– Renal diseases No 17 89.5
Yes 2 10.5
– Liver diseases No 17 89.5
Yes 2 10.5
– Neurological impairment No 17 89.5
Yes 2 10.5




– Oncological diseases No 16 84.2
Yes 3 15.8




– Dementia No 19 100
Yes 0 0
– Transplantation of solid organs No 19 100
Yes 0 0






– Tuberculosis No 19 100
Yes 0 0
– Other diseases No 7 36.8
Yes 12 63.2
Had at least one complication Unknown 9 13.2
No 30 44.1
Yes 29 42.6








– Respiratory complications No 13 44.8
Yes 16 55.2
– Acute respiratory distress syn-





complications) No 11 68.8
Yes 4 25










– Cardiovascular complications No 23 79.3
Yes 6 20.7
– Digestive complications No 22 75.9
Yes 7 24.1
– Liver complications No 22 75.9
Yes 7 24.1
– Renal complications No 26 89.7
Yes 3 10.3




– Osteo-articular complications No 29 100
Yes 0 0
– Thrombosis/embolism No 26 89.7
Yes 3 10.3
– Other bacterial infection No 29 100
Yes 0 0
– Other non-bacterial infection No 27 93.1
Yes 2 6.9
– Other complications No 15 51.7
Yes 14 48.3
Stayed in ICU at least once Unknown 8 11.8
No 54 79.4
Yes 6 8.8





– Hydroxychloroquine No 2 50
Yes 2 50
– Interferon No 4 100
Yes 0 0
– Lopinavir/ritonavir No 4 100
Yes 0 0
– Remdesivir No 3 75
Yes 1 25
– Tenofovir No 4 100
Yes 0 0
– Ribavirin No 4 100
Yes 0 0
– Other treatment No 1 25
Yes 3 75







HIV = human immunodeficiency virus; ICU = intensive care unit
episodes. The information was missing for 596 (16.3%) of
the 3650 episodes.
Drug treatments
The distribution of drugs prescribed against the COVID-19
infection can be found in tables 2 and 3. In 1299 episodes
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(35.6% overall, 36.2% of episodes in adults and 5.9% of
all episodes in children), one or often a combination of
therapeutic agents were used. Hydroxychloroquine was the
most prescribed treatment against COVID-19 (989, 76.1%;
985 in adults and 2 in children) followed by lopinavir/
ritonavir (675, 52.0%; exclusively in adults). Remdesivir
was the third most predominant drug used to treat
COVID-19 (146, 11.2%; only once in children). Other
treatments were prescribed rarely (interferon twice and
tenofovir once), or not at all (ribavirin). Note that hydrox-
ychloroquine was almost abandoned once no more recom-
mended by international and national authorities.
Outcomes
Figure 3 shows the cumulative number of episodes, dis-
charges and deaths reported in the database. Among the
3650 episodes, 2989 (81.9%) were reported be followed by
discharge from the hospital, among which 2275 were dis-
charged to their domicile, 230 to another hospital. 222 to a
long-term care facility and 249 to other locations such as
rehabilitation centres.
Death was reported in 527 episodes (14.4%), none in chil-
dren. The first death occurred in the week following the
first recorded episode (2020-10). The number of reported
deaths increased rapidly during the first 10 weeks, with on-
ly a small number of deaths occurring after week 2020-20.
Figure 4 shows the number of death versus the time be-
tween the date of interest for the surveillance and the death
date. Most deaths occurred in patients with comorbidities
(431, 81.8%) within the first two weeks following their di-
agnosis, with a median time between diagnosis and death
of 8 days (IQR 5–14 days). Overall, deaths were mostly in
patients aged between 80 and 89 years (224, 42.5%) and in
patients between 70 and 79 years (147, 27.8%) as seen in
figure 5. No deaths were reported for patients below 30.
Pregnant women
Pregnancy was present in 5.9% (35) of episodes in repro-
ductive women (i.e., between 15 and 50 years old) reg-
istered in the database. Among those, 16 suffered from
comorbidities (3 asthma, 3 diabetes, 2 hypertension and
14 other comorbidities), and 14 complications occurred,
mostly respiratory complications (7 episodes) and ENT
complications (4 episodes). Only one pregnant woman
stayed in the ICU. None of them received antiviral treat-
ment for COVID-19, and no deaths were reported.
Healthcare workers
A total of 146 (4.0%) patients were employed in a health-
care facility: one (0.7%) was infected in a hospital and six
(4.1%) were of unknown source.
Strengths and limitations
By using an existing surveillance system for influenza and
adapting it for the surveillance of SARS-CoV-2/
COVID-19 cases, we quickly developed a large har-
monised dataset of hospitalised COVID-19 cases in
Switzerland. The data enable assessment of disease sever-
ity, risk factors, treatments and the clinical course of the
disease. The data are useful for informing public health au-
thorities and policy makers on the impact of health regula-
tions put in place during the pandemic and has the poten-
tial to be used in modelling the future of the disease in the
country. Due to the lack of data at the European level when
Figure 3: Cumulative number of episodes, discharges and deaths related to COVID-19 infection in the database.
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the pandemic started in Europe, most models and mea-
sures taken against COVID-19 in Switzerland were based
Figure 4: Distribution of deceased patients within the database.
Figure 5: Population breakdown of the 527 deceased patients hospitalised with COVID 19 between 1 March and 31 August 2020 by age and
gender.
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on Chinese data. The data obtained during this first wave
will therefore enable healthcare workers and policy makers
to respond more efficiently to the disease in the future.
Despite the system being rapidly set up, its use for real-
time monitoring of the epidemic presented some chal-
lenges. Discussions with the FOPH on adapting the exist-
ing influenza database started in early February and the
system was fully operational by the end of the same month,
shortly after the first case was declared in Switzerland.
This highlights the adaptability of the original system for
surveillance of other respiratory viruses. Despite the
strength of the system in place, it was difficult to obtain da-
ta within 48 hours of the diagnosis for most centres faced
with a high number of cases. Some hospitals started the da-
ta collection later than others, and had to enter data both
retrospectively and prospectively. Other centres were over-
whelmed by the large number of cases and had to focus on
patient care first, while at the same time trying to train new
staff who could help with data entry. The overall median
time difference between the first positive laboratory test
and the inclusion in the database was 13 days (IQR 3–28).
Figure 6 shows the time delay throughout the pandem-
ic. The maximum delay was observed during the height
of the epidemic in Switzerland, but quickly decreased as
the number of cases decreased. Note that other Swiss en-
tities also requested data from several participating hospi-
tals, making it more difficult for them to report episodes
within the required 48 hours.
Using the same approach as the influenza database, data
were checked weekly for inconsistencies and reported to
the participating hospitals and the FOPH. Outliers in dates,
impossible combinations of variables, length of stays and
treatments, out of range numbers and missing values were
consistently checked. This allowed the participating hospi-
tals to correct wrong and missing data rapidly. Additional
checks on the data, based on the patients’ records, were
made by the supervising physicians in each hospital to en-
sure medical accuracy.
By including a large number of university and cantonal
hospitals, we collected 3650 cases confirmed by PCR as
of 1 September 2020 and 527 (14.7%) COVID-19 related
deaths. On the same date, the mandatory reporting system
put in place by the FOPH [14] had registered 4588 con-
firmed hospitalised patients related to COVID-19. Among
these hospitalised patients, 945 (20.6%) died during their
hospital stay. Overall, 59.9% of patients were male and
40.0% female. Comorbidities were observed in 3475
(75.7%) patients. Among thoese were hypertension in
60.8% of the patients, chronic cardiovascular diseases in
39.2%, diabetes in 27.4%, chronic respiratory diseases in
18.2%, oncological disease in 11.6% and immunosuppres-
sion in 4.9%. Those numbers match with the proportions
found in the hospital database, except for hypertensive
patients, cardiovascular pathologies and patients suffering
from diabetes, for which the FOPH reporting system found
higher proportions. The median age of the patients in the
compulsory declaration system was also slightly higher
than that in our database (70 versus 68 years old). Table 4
summarises the findings from the mandatory system.
We nevertheless included approximatively 80% of the total
number of SARS-CoV-2/COVID-19 hospitalised patients
reported in the obligatory system of the FOPH up to 1 Sep-
tember 2020. The lower proportion of deaths in our sys-
tem suggests that many patients may have died after dis-
Figure 6: Time delay (in days) between the date of interest for the system and the inclusion of the patient in the database.
Original article Swiss Med Wkly. 2021;151:w20475
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 10 of 13
Table 4: Characteristics of COVID-19/SARS-CoV-2 patients hospi-
talised up to 1 September 2020, in the mandatory reporting system of




Gender Male 2749 59.9
Female 1837 40.0
Other 2 0.0



















– Diabetes Yes 951 27.4
No or Unknown 2524 72.6
– Cardiovascular diseases Yes 1361 39.2
No or Unknown 2114 60.8
– Hypertension Yes 2112 60.8
No or Unknown 1363 39.2
– Respiratory diseases Yes 633 18.2
No or Unknown 2842 81.8
– Oncological diseases Yes 405 11.6
No or Unknown 3070 88.3
– Immunosuppressed Yes 171 4.9
No or Unknown 3304 95.1
– Other Yes 1608 46.3
No or Unknown 1867 53.7
Outcome Deceased 945 20.6
Alive 3644 79.4
Note: The age group <1year encompasses the <1 month and 1
month–5 years age group from our system, as the mandatory reporting
system data contains age in years without decimals and no date of
birth. Official data do not allow for separation between “No” and “Un-
known”, hence their common category. Data courtesy of FOPH.
charge from the hospital, in another institution not captured
by the system, or among patient hospitalised for less than
24 hours. We were also missing data on adult patients from
three hospitals that only agreed to contribute paediatric
cases, potentially explaining the difference in the median
age in both systems.
Conclusion and outlooks
The setting-up of this database is a first step towards an in-
depth understanding of the SARS-CoV-2/COVID-19 epi-
demic in Switzerland, and is a powerful tool for the second
wave, initially reported in China [15] and currently occur-
ring in Europe. The data will allow authorities to tackle
risk populations more precisely and adapt restrictions. The
system was easily adapted from the influenza surveillance
system in a matter of days by including and removing dis-
ease-specific information, which allowed a fast response
in obtaining data. However, the lack of human resources,
the severity of the pandemic and the multiplication of
COVID-19 data collection in hospitals by Swiss medical
societies and authorities made it difficult to obtain data
rapidly. Therefore, timely monitoring of the epidemic was
difficult, an issue that needs to be addressed rapidly for fu-
ture pandemics by working more closely with officials to
avoid overlapping demands.
Despite the drawback, of the database as a monitoring
tool, the robust coverage of patients when compared to the
mandatory reporting system makes it a powerful addition
to the mandatory reporting system by adding more detailed
information on the epidemiology, risk factors and clinical
course of hospitalised patients, which is missing from the
official system.
The surveillance is still ongoing and we plan, in the future,
to include patients with negative PCR results but a sugges-
tive clinical presentation combined with radiographic find-
ings compatible with COVID-19, and patients with posi-
tive SARS-CoV-2 serology. We will distinguish these three
modes of diagnosis: positive PCR ensures that the virus
is present, whereas computed tomography and radiography
show specific features of COVID-19 resulting in only a
suspected diagnosis. Positive serology indicates that a pa-
tient was previously infected, and could therefore be of in-
terest for hospitalisations due to complications of the in-
fection (e.g., if the patient was not initially hospitalised).
There are ongoing discussions on linking patients from the
database to their biological samples, in order to study as-
sociations between risk factors, complications and specific
strains of the virus and, therefore, possibly establish micro-
biological surveillance of the disease.
Finally, we plan to study long-term consequences of infec-
tions, since the system allows us to track several hospital
stays in affected patients.
Accessing the data
The anonymised data can be accessed through a multi-
stage process. Applicants must fill a concept-sheet (avail-
able in appendix 2) and send it to the team in charge of the
study. An Executive Committee of experts and representa-
tives of participating hospital will review the concept. De-
pending on the goal of the analysis, additional ethics clear-
ance might be needed. Data will be restricted to the request
and shared through a secure platform. All steps to access
the data are described in the aforementioned concept-sheet,
including contact details. Additional information can be
found on the dedicated website: https://www.unige.ch/
medecine/hospital-covid/.
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